In a phase III randomized clinical trial,18 atezolizumab plus bevacizumab improved PFS vs sunitinib in a subset of patients with PD-L1–positive metastatic kidney cell carcinoma (HR, 0.74; P = .022), and lastly, a phase Ib trial19 of pembrolizumab + lenvatinib for head and neck squamous cell carcinoma found an ORR of 36.4%. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.